Compare CLFD & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLFD | BWAY |
|---|---|---|
| Founded | 1979 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.2M | 450.8M |
| IPO Year | 1995 | N/A |
| Metric | CLFD | BWAY |
|---|---|---|
| Price | $30.01 | $12.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $43.50 | $13.25 |
| AVG Volume (30 Days) | ★ 90.7K | 85.8K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,034,000.00 | N/A |
| Revenue This Year | $11.64 | $314.08 |
| Revenue Next Year | $22.30 | $23.37 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | ★ 9.51 | N/A |
| 52 Week Low | $23.78 | $7.84 |
| 52 Week High | $46.76 | $26.63 |
| Indicator | CLFD | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 43.05 | 22.57 |
| Support Level | $28.25 | $11.44 |
| Resistance Level | $31.22 | $17.20 |
| Average True Range (ATR) | 1.20 | 1.34 |
| MACD | -0.24 | -1.46 |
| Stochastic Oscillator | 4.04 | 3.46 |
Clearfield Inc designs, manufactures, and distributes fiber protection, fiber management, and fiber delivery solutions to enable rapid and cost-effective fiber-fed deployment throughout the broadband service provider space prominently across North America. Its 'fiber to anywhere' platform serves the requirements of Community Broadband customers, Multiple System Operators, Large Regional Service Providers, National Carriers, and International customers (including Europe, Canada, Mexico, and Caribbean Markets). Its product offerings include Accessories, Cassettes, Cable & Drop Assemblies, Frames & Panels, Microducts, Optical Components, etc. The company derives the majority of its revenue from the United States.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.